Avacta : Presenting at the Biotech Showcase, San Francisco

For immediate release

3 January 2018

Avacta Group plc

('Avacta' or 'the Group' or 'the Company')

Presenting at the Biotech Showcase, San Francisco

Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, is pleased to announce that its Chief Executive Officer, Dr Alastair Smith, will be presenting at the annual Biotech Showcase, 8-10 January 2018, San Francisco.

Dr Smith will outline the key benefits of the Affimer® technology as a therapeutic protein platform and update the meeting on progress within the Group's therapeutic programmes.

The presentation will be available on Avacta's website (www.avacta.com).

- Ends -

For further information from Avacta Group plc, please contact:

Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer	Tel: [phone] www.avacta.com
finnCap Ltd Geoff Nash / Giles Rolls - Nominated Adviser Tim Redfern / Alice Lane / Nikita Jain - Corporate Broking WG Partners Nigel Birks / Nigel Barnes David Wilson / Claes Spang	Tel: [phone] www.finncap.com Tel: [phone] Tel: [phone] www.wgpartners.co.uk
Zyme Communications(Trade and Regional Media) Katie Odgaard Yellow Jersey PR(Financial Media and IR) Sarah Hollins	Tel: [phone] [e-mail] Tel: [phone] [e-mail]

About Avacta Group plc(www.avacta.com)

Avacta's principal focus is on its proprietary Affimer technology which is anovel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology isbased on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

To register for news alerts by email go towww.avacta.com/investor-news-email-alerts